Does the biomarker search paradigm need re-booting?
The clinical problem of bladder cancer is its high recurrence and progression, and that the most sensitive and specific means of monitoring is cystoscopy, which is invasive and has poor patient compliance. Biomarkers for recurrence and progression could make a great contribution, but in spite of decades of research, no biomarkers are commercially available with the requisite sensitivity and specificity. In the post-genomic age, the means to search the entire genome for biomarkers has become available, but the conventional approaches to biomarker discovery are entirely inadequate to yield results with the new technology. Finding clinically useful biomarker panels with sensitivity and specificity equal to that of cystoscopy is a problem of systems biology.
Hurst
Robert E
RE
D014408:Biomarkers, Tumor / Q000032:analysis*; D035843:Biomedical Research / Q000639:trends*; D002986:Clinical Trials as Topic / Q000639:trends*; D006801:Humans; D009363:Neoplasm Proteins / Q000032:analysis*; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000378:metabolism*
D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins